Seizures and cerebritis associated with administration of OKT3.
The development of a self-limited aseptic meningitis usually following the first dose administration of OKT3 therapy (an anti-pan-T-cell monoclonal antibody) in the treatment of renal transplantation rejection is well-documented. This report describes a patient with renal transplantation rejection who developed lateralizing seizures and cerebritis documented by magnetic resonance imaging. These findings were associated with the initiation of OKT3 therapy. To our knowledge, both cerebritis and seizures have not been described in association with OKT3 therapy.